司美格鲁肽联合胰岛素治疗2型糖尿病合并肥胖患者的临床效果OA

Objective To explore the efficacy and safety of Semaglutide combined with insulin in patients with type 2 dia-betes mellitus complicated with obesity.Methods A total of 80 patients with type 2 diabetes mellitus complicated with obe-sity admitted to Aviation General Hospital from June 2023 to September 2025 were selected as the study subjects,and they were divided into the control group and the observation group according to the actual treatment methods,with 40 cases in each group.The control group received insulin monotherapy,while the observation group received Semaglutide combined with insulin therapy.The treatment efficacy,blood glucose indicators,physical indicators,and adverse reactions of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the con-trol group,and the difference was statistically significant(P<0.05).After treatment,the fasting blood glucose,2-hour post-meal blood glucose,and insulin resistance index in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the body mass index,waist circumference,hip circumference,and waist-to-hip ratio in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients with type 2 diabetes mellitus complicated with obesity,the combination of Semaglutide on the basis of insulin therapy can significantly improve the overall treatment effectiveness rate,enhance blood glucose control levels and insulin sensitivity,and effectively reduce obesity-related physical indicators such as body mass index,waist circumference,hip circumference and waist-hip ratio without increasing the risk of adverse reactions.It has good clinical application safety.